(Boursier.com) — Guerbet (GBT) obtains funding of one million euros from the State via France 2030 following its participation in a call for projects concerning the acceleration strategy in digital health. The presentation of the work of Guerbet’s Artificial Intelligence (AI) research team, which could potentially offer a promising response to a medical need, convinced the jury to support this project with public funding.
Pancreatic cancer represents 496,000 cases per year, including 14,500 in France and 56,700 in the USA. The number of patients with this disease has doubled over the past 25 years. The mortality rate of patients is high with a survival ranging from 1 to 5 years depending on the stage of the disease at the time of diagnosis. It is expected to be the 3rd leading cause of death from cancer in the EU and the 4th in the USA by 2040.
Surgery is the only potentially curative treatment but is only possible in the early stages of the disease. However, less than 20% of patients are candidates, because of these detections which are often too late.
The early stages are often asymptomatic and the discovery of this cancer is often fortuitous and late.
©2022 Boursier.com